|1.||Pitt, Bertram: 28 articles (11/2015 - 05/2002)|
|2.||Fujita, Toshiro: 27 articles (01/2016 - 02/2007)|
|3.||Funder, John W: 26 articles (06/2012 - 08/2002)|
|4.||Nagase, Miki: 18 articles (01/2016 - 02/2007)|
|5.||Young, Morag J: 18 articles (11/2015 - 07/2006)|
|6.||Sowers, James R: 15 articles (12/2015 - 07/2008)|
|7.||Jaisser, Frederic: 14 articles (07/2015 - 05/2002)|
|8.||Zannad, Faiez: 14 articles (07/2015 - 11/2011)|
|9.||Farman, Nicolette: 13 articles (12/2015 - 05/2002)|
|10.||Leenen, Frans H H: 12 articles (10/2014 - 05/2005)|
02/01/2015 - "To investigate the safety and potential efficacy of the novel non-steroidal mineralocorticoid receptor antagonist finerenone in patients with worsening chronic heart failure and reduced left ventricular ejection fraction (HFrEF) and at high risk of hyperkalaemia and worsening renal dysfunction. "
02/01/2010 - "Using mineralocorticoid receptor antagonists a significant reduction in mortality was archived in patients with heart failure. "
09/01/2012 - "Mineralocorticoid receptor antagonists (MRAs) have been effective in reducing total mortality in patients with heart failure (HF) and a reduced left ventricular ejection fraction. "
09/07/2014 - "Evaluating the efficacy of mineralocorticoid receptor antagonism in patients with STEMI without heart failure."
07/01/2014 - "Pharmacological blockade of the mineralocorticoid receptor (MR) ameliorates end-organ damage in chronic heart failure. "
|2.||Hypertension (High Blood Pressure)
01/01/2011 - "Chronic antagonism of the mineralocorticoid receptor ameliorates hypertension and end organ damage in a rodent model of salt-sensitive hypertension."
09/01/2001 - "In this review, the mechanism by which the mutation causes hypertension, and the implications these findings have for improved understanding of cardiovascular physiology and mineralocorticoid receptor biology, are discussed."
10/01/2014 - "We report the results of an echocardiographic substudy carried out in a trial comparing the effects of two different treatment strategies - mineralocorticoid receptor blockade (MRB) and dual renin-angiotensin system blockade (RASB) - in patients with resistant hypertension. "
07/01/2006 - "The aim of this study was to determine the effect of RNA interference inhibition of mineralocorticoid receptor (MR) on cold-induced hypertension (CIH) and renal damage. "
12/15/2015 - "CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats."
|3.||Kidney Diseases (Kidney Disease)
01/01/2015 - "Steroidal mineralocorticoid receptor antagonists (MRAs) are effective in the treatment of kidney disease; however, the side effect of hyperkalaemia, particularly in the context of renal impairment, is a major limitation to their clinical use. "
12/01/2009 - "Further studies will need to be conducted to determine whether mineralocorticoid receptor blockers are equally effective and safe for the treatment of chronic kidney disease in children."
12/01/2008 - "Blockade of mineralocorticoid receptor has been shown to improve the clinical outcomes of proteinuric kidney diseases. "
09/01/2015 - "Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials."
06/01/2010 - "This trial is expected to show whether a low dose of mineralocorticoid receptor antagonists can exert an antialbuminuric effect in patients with chronic kidney disease."
08/01/2013 - "Recent studies using cell-specific deletion of the mineralocorticoid receptor indicate that its activation in macrophages is a key step in the development of cardiac fibrosis in the setting of hemodynamic or hormonal challenges. "
05/01/2015 - "Mineralocorticoid receptor antagonism enhanced M2 macrophage polarization and ameliorated oxidant stress and fibrosis. "
05/01/2015 - "Originally, the research focus for mineralocorticoid-induced fibrosis was on the collecting duct, where 'classical' mineralocorticoid receptors (MRs) involved with electrolyte transport are present. "
11/01/2014 - "Mineralocorticoid receptor blockers show antifibrotic potential in hepatic fibrosis. "
03/07/2014 - "We studied the role of the mineralocorticoid receptor (MR) in the signaling that promotes atrial fibrosis. "
02/01/2011 - "Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction."
01/01/2015 - "Retrospective review of in hospital use of mineralocorticoid receptor antagonists for high risk patients following myocardial infarction."
01/01/2014 - "In murine models of myocardial infarction, mineralocorticoid receptor antagonists reduce infarct size. "
12/01/2013 - "Central mechanisms involving mineralocorticoid receptor (MR) activation contribute to an increase in sympathetic tone after myocardial infarction (MI). "
10/01/2012 - "Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances."
|5.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|6.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|8.||Angiotensin Receptor Antagonists
|2.||Sodium-Restricted Diet (Diet, Sodium Restricted)
|3.||Renal Dialysis (Hemodialysis)
|4.||Infant Equipment (Crib)